JP2010270125A - 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 - Google Patents
機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 Download PDFInfo
- Publication number
- JP2010270125A JP2010270125A JP2010151403A JP2010151403A JP2010270125A JP 2010270125 A JP2010270125 A JP 2010270125A JP 2010151403 A JP2010151403 A JP 2010151403A JP 2010151403 A JP2010151403 A JP 2010151403A JP 2010270125 A JP2010270125 A JP 2010270125A
- Authority
- JP
- Japan
- Prior art keywords
- glp
- irritable bowel
- bowel syndrome
- pharmaceutical composition
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
【解決手段】消化管において抗分泌作用および平滑筋弛緩特性を有するグルカゴン様ペプチド−1(GLP−1)およびその誘導体からなるクラスから選択される消化管ペプチドホルモンを機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物。また、GLP−1およびその誘導体からなる上記クラスから選択される少なくとも1つと1つ以上の他の消化管ペプチドホルモンまたはその誘導体とを組み合わせて、薬理学的に許容される添加剤とともに含有する医薬組成物、ならびに、GLP−1およびその誘導体からなる上記クラスの少なくとも1つの有効量を投与することによって、機能性消化不良もしくは過敏性腸症候群またはその両方を治療する方法。
【選択図】なし
Description
Claims (7)
- 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物を製造するための、消化管において抗分泌作用および平滑筋弛緩特性を有するグルカゴン様ペプチド−1(GLP−1)ならびにその誘導体からなるクラスから選択される消化管ペプチドホルモンの使用。
- 前記医薬組成物において、前記GLP−1またはその誘導体が1つ以上の他の消化管ペプチドホルモンまたは誘導体と組み合わせられている、請求項1記載の使用。
- 前記医薬組成物において、ソマトスタチンがGLP−1と組み合わせられている、請求項2記載の使用。
- 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物であって、消化管において抗分泌作用および平滑筋弛緩特性を有するGLP−1ならびにその誘導体からなる群から選択される少なくとも1つと、そのような作用および特性を有する1つ以上の他の消化管ペプチドホルモンならびにその誘導体との組み合わせを、薬理学的に許容される添加剤とともに含有することを特徴とする医薬組成物。
- GLP−1と併せてソマトスタチンを含有することを特徴とする、請求項4記載の医薬組成物。
- 機能性消化不良もしくは過敏性腸症候群またはその両方に罹患しているヒト患者において、機能性消化不良もしくは過敏性腸症候群またはその両方を治療する方法であって、消化管において抗分泌作用および平滑筋弛緩特性を有するGLP−1ならびにその誘導体からなる群の少なくとも1つの有効量を該患者に投与することを含む方法。
- ソマトスタチンと併せてGLP−1を投与する、請求項6記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802080A SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000553128A Division JP2002517468A (ja) | 1998-06-11 | 1999-06-08 | 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010270125A true JP2010270125A (ja) | 2010-12-02 |
Family
ID=20411665
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000553128A Ceased JP2002517468A (ja) | 1998-06-11 | 1999-06-08 | 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 |
JP2010151403A Pending JP2010270125A (ja) | 1998-06-11 | 2010-07-01 | 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000553128A Ceased JP2002517468A (ja) | 1998-06-11 | 1999-06-08 | 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 |
Country Status (19)
Country | Link |
---|---|
US (1) | US6348447B1 (ja) |
EP (2) | EP1405642A1 (ja) |
JP (2) | JP2002517468A (ja) |
AT (1) | ATE252912T1 (ja) |
AU (1) | AU738994B2 (ja) |
CA (1) | CA2321700C (ja) |
CZ (1) | CZ300873B6 (ja) |
DE (1) | DE69912434T2 (ja) |
DK (1) | DK1094834T3 (ja) |
ES (1) | ES2205845T3 (ja) |
HU (1) | HUP0103147A3 (ja) |
NO (1) | NO327738B1 (ja) |
NZ (1) | NZ506163A (ja) |
PL (1) | PL198802B1 (ja) |
PT (1) | PT1094834E (ja) |
RU (1) | RU2226402C2 (ja) |
SE (1) | SE9802080D0 (ja) |
WO (1) | WO1999064060A1 (ja) |
ZA (1) | ZA200004080B (ja) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
CA2377204C (en) | 1999-06-29 | 2015-01-20 | Pharmaceutical Discovery Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
EP1267912A2 (en) * | 2000-03-14 | 2003-01-02 | Burkhard Göke | Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
CA2407784C (en) | 2000-05-19 | 2014-08-26 | Bionebraska, Inc. | Treatment of acute coronary syndrome with glp-1 |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1478233B1 (en) | 2002-02-20 | 2016-11-09 | Emisphere Technologies, Inc. | Method for administering glp-1 molecules |
SI1494732T1 (sl) | 2002-03-20 | 2008-08-31 | Mannking Corp | Inhalacijski aparat |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
US7452966B2 (en) | 2003-06-12 | 2008-11-18 | Eli Lilly And Company | GLP-1 analog fusion proteins |
ES2338789T3 (es) * | 2003-06-18 | 2010-05-12 | Tranzyme Pharma Inc. | Antagonistas macrociclicos del receptor de motilina. |
US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
KR101306384B1 (ko) | 2004-08-23 | 2013-09-09 | 맨카인드 코포레이션 | 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염 |
WO2006111169A1 (en) * | 2005-04-21 | 2006-10-26 | Gastrotech Pharma A/S | Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug |
CN101166545B (zh) | 2005-05-13 | 2011-06-15 | 伊莱利利公司 | Glp-1聚乙二醇化的化合物 |
CA2617859A1 (en) | 2005-06-30 | 2007-01-11 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Glp-1 pharmaceutical compositions |
EP2394702B1 (en) * | 2005-07-29 | 2014-12-31 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
AU2006290227B2 (en) | 2005-09-14 | 2012-08-02 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
RU2403059C2 (ru) | 2006-02-22 | 2010-11-10 | Маннкайнд Корпорейшн | Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент |
MX2009006942A (es) * | 2006-12-29 | 2009-11-09 | Ipsen Pharma Sas | Composiciones farmaceuticas de glp-1. |
WO2008134425A1 (en) * | 2007-04-27 | 2008-11-06 | Cedars-Sinai Medical Center | Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders |
US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
EP2211842B1 (en) * | 2007-10-24 | 2015-08-12 | MannKind Corporation | An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration |
AU2008316636B2 (en) * | 2007-10-24 | 2014-02-06 | Mannkind Corporation | Delivery of active agents |
KR101629154B1 (ko) | 2008-06-13 | 2016-06-21 | 맨카인드 코포레이션 | 건조 분말 흡입기 및 약물 투여 시스템 |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
CA2727147A1 (en) | 2008-06-17 | 2009-12-23 | Otsuka Chemical Co., Ltd. | Glycosylated glp-1 peptide |
DK2300083T3 (da) | 2008-06-20 | 2013-07-22 | Mannkind Corp | Interaktivt apparat og fremgangsmåde til realtids-profilering af inhalationsforsøg |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
EP2216042A1 (en) | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP-1 analogues pharmaceutical compositions |
MX2011009512A (es) | 2009-03-11 | 2011-11-29 | Mannkind Corp | Aparato, sistema y metodo para medir la resistencia de un inhalador. |
US8614185B2 (en) | 2009-05-04 | 2013-12-24 | Centocor Ortho Biotech Inc. | Fusion proteins of alpha-MSH derivatives and Fc |
WO2010129248A1 (en) | 2009-05-06 | 2010-11-11 | Centocor Ortho Biotech Inc. | Melanocortin receptor binding conjugates |
SG176738A1 (en) | 2009-06-12 | 2012-01-30 | Mannkind Corp | Diketopiperazine microparticles with defined specific surface areas |
WO2011013728A1 (ja) * | 2009-07-29 | 2011-02-03 | 第一三共株式会社 | 経粘膜吸収性を付与したモチリン類似ペプチド化合物 |
JPWO2011052523A1 (ja) | 2009-10-30 | 2013-03-21 | 株式会社糖鎖工学研究所 | 抗原性glp−1アナログの糖鎖付加体 |
CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
US9168288B2 (en) * | 2010-04-09 | 2015-10-27 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist |
EA023925B1 (ru) | 2010-04-27 | 2016-07-29 | Зилэнд Фарма А/С | Пептидные конъюгаты агонистов рецептора glp-1 и их применение |
BR112012033060A2 (pt) | 2010-06-21 | 2018-02-27 | Mannkind Corp | métodos de sistema de liberação de fármaco em pó seco |
CN103080125A (zh) | 2010-07-02 | 2013-05-01 | 安吉奥开米公司 | 用于治疗性结合物的短且含d氨基酸的多肽及其使用 |
DK3326620T3 (da) | 2010-12-16 | 2020-05-25 | Novo Nordisk As | Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre |
CN105667994B (zh) | 2011-04-01 | 2018-04-06 | 曼金德公司 | 用于药物药盒的泡罩包装 |
KR101972836B1 (ko) | 2011-04-12 | 2019-04-29 | 노보 노르디스크 에이/에스 | 이중 아실화된 glp-1 유도체 |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
JP6359972B2 (ja) | 2011-11-03 | 2018-07-18 | ジーランド ファーマ アクティーゼルスカブ | Glp−1受容体アゴニストペプチドガストリンコンジュゲート |
HUE062740T2 (hu) * | 2012-03-22 | 2023-12-28 | Novo Nordisk As | GLP-1 peptidek készítményei és elõállításuk |
DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
US10335369B2 (en) | 2012-03-22 | 2019-07-02 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
ES2871328T3 (es) | 2012-06-20 | 2021-10-28 | Novo Nordisk As | Formulación de comprimido que comprende un péptido y un agente de suministro |
SG10201605800UA (en) | 2012-07-12 | 2016-09-29 | Mannkind Corp | Dry powder drug delivery system and methods |
BR112015001451B1 (pt) | 2012-07-23 | 2022-03-29 | Zealand Pharma A/S | Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
JP6523247B2 (ja) | 2013-03-15 | 2019-05-29 | マンカインド コーポレイション | 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法 |
CN114848614A (zh) | 2013-07-18 | 2022-08-05 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
MY176022A (en) | 2013-10-17 | 2020-07-21 | Boehringer Ingelheim Int | Acylated glucagon analogues |
EP3065767B1 (en) | 2013-11-06 | 2020-12-30 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
KR101825048B1 (ko) | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
PL3257524T3 (pl) | 2015-02-11 | 2021-03-08 | Gmax Biopharm Llc | Stabilny preparat farmaceutyczny w postaci roztworu białka fuzyjnego przeciwciała przeciwko glp-1r |
CA2980978A1 (en) | 2015-04-16 | 2016-10-20 | Zealand Pharma A/S | Acylated glucagon analogue |
DK3551651T3 (da) | 2016-12-09 | 2024-05-13 | Zealand Pharma As | Acylerede glp-1/glp-2-dobbeltagonister |
CN111683676B (zh) | 2018-02-02 | 2024-06-18 | 诺和诺德股份有限公司 | 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物 |
CN110305211A (zh) | 2018-03-20 | 2019-10-08 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
CN112521501A (zh) | 2019-09-18 | 2021-03-19 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY147327A (en) * | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
US5994500A (en) * | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
-
1998
- 1998-06-11 SE SE9802080A patent/SE9802080D0/xx unknown
-
1999
- 1999-06-08 PL PL343104A patent/PL198802B1/pl not_active IP Right Cessation
- 1999-06-08 CZ CZ20004491A patent/CZ300873B6/cs not_active IP Right Cessation
- 1999-06-08 AT AT99930089T patent/ATE252912T1/de not_active IP Right Cessation
- 1999-06-08 AU AU46697/99A patent/AU738994B2/en not_active Ceased
- 1999-06-08 EP EP20030024624 patent/EP1405642A1/en not_active Withdrawn
- 1999-06-08 PT PT99930089T patent/PT1094834E/pt unknown
- 1999-06-08 RU RU2000133249/14A patent/RU2226402C2/ru not_active IP Right Cessation
- 1999-06-08 US US09/445,571 patent/US6348447B1/en not_active Expired - Lifetime
- 1999-06-08 EP EP99930089A patent/EP1094834B1/en not_active Expired - Lifetime
- 1999-06-08 ES ES99930089T patent/ES2205845T3/es not_active Expired - Lifetime
- 1999-06-08 NZ NZ506163A patent/NZ506163A/en unknown
- 1999-06-08 CA CA2321700A patent/CA2321700C/en not_active Expired - Fee Related
- 1999-06-08 DE DE69912434T patent/DE69912434T2/de not_active Expired - Lifetime
- 1999-06-08 WO PCT/SE1999/000997 patent/WO1999064060A1/en active IP Right Grant
- 1999-06-08 JP JP2000553128A patent/JP2002517468A/ja not_active Ceased
- 1999-06-08 HU HU0103147A patent/HUP0103147A3/hu unknown
- 1999-06-08 DK DK99930089T patent/DK1094834T3/da active
-
2000
- 2000-08-10 ZA ZA200004080A patent/ZA200004080B/xx unknown
- 2000-12-06 NO NO20006194A patent/NO327738B1/no not_active IP Right Cessation
-
2010
- 2010-07-01 JP JP2010151403A patent/JP2010270125A/ja active Pending
Non-Patent Citations (5)
Title |
---|
JPN6009037628; Regulatory Peptides Vol.74,No.1, 199804, p19-25 * |
JPN6009037629; Journal of Pharmacology and Experimental Therapeut Vol.268,No.3, 1994, p1206-1211 * |
JPN6012039589; Scandinavian Journal of Gastroenterology. Suppleme Vol.116, 1985, p1-48 * |
JPN6012039591; Scandinavian Journal of Gastroenterology Vol.20,No.10, 1985, p1163-1168 * |
JPN6012039594; Therapeutic Research Vol.7,No.6, 1987, p1215-1226 * |
Also Published As
Publication number | Publication date |
---|---|
NO20006194D0 (no) | 2000-12-06 |
PT1094834E (pt) | 2004-03-31 |
DK1094834T3 (da) | 2004-01-05 |
AU4669799A (en) | 1999-12-30 |
EP1094834A1 (en) | 2001-05-02 |
ZA200004080B (en) | 2001-12-24 |
SE9802080D0 (sv) | 1998-06-11 |
ATE252912T1 (de) | 2003-11-15 |
NO20006194L (no) | 2001-01-25 |
CZ300873B6 (cs) | 2009-09-02 |
WO1999064060A1 (en) | 1999-12-16 |
CZ20004491A3 (en) | 2001-05-16 |
CA2321700C (en) | 2011-05-03 |
HUP0103147A3 (en) | 2002-02-28 |
HUP0103147A2 (hu) | 2002-01-28 |
NO327738B1 (no) | 2009-09-14 |
US6348447B1 (en) | 2002-02-19 |
DE69912434T2 (de) | 2004-05-06 |
NZ506163A (en) | 2004-10-29 |
CA2321700A1 (en) | 1999-12-16 |
PL198802B1 (pl) | 2008-07-31 |
RU2226402C2 (ru) | 2004-04-10 |
EP1405642A1 (en) | 2004-04-07 |
EP1094834B1 (en) | 2003-10-29 |
JP2002517468A (ja) | 2002-06-18 |
DE69912434D1 (de) | 2003-12-04 |
AU738994B2 (en) | 2001-10-04 |
PL343104A1 (en) | 2001-07-30 |
ES2205845T3 (es) | 2004-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010270125A (ja) | 機能性消化不良および/または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用 | |
Wiseman et al. | Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders | |
Grosman et al. | Potential gastrointestinal uses of somatostatin and its synthetic analogue octreotide. | |
Scarpignato et al. | Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility | |
RU2432167C2 (ru) | Способ уменьшения симптомов изжоги и гастроэзофагиальной рефлюксной болезни (гэрб) с помощью особых полисахаридов | |
RU2000133249A (ru) | Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней | |
KR20010041211A (ko) | 안지오텐신 ιι 타입 2 수용체 효능제를 포함하는 제약제제 및 그의 용도 | |
Van der Sijp et al. | Circulating gastrointestinal hormone abnormalities in patients with severe idiopathic constipation | |
Walt et al. | Comparison of twice-daily ranitidine with standard cimetidine treatment of duodenal ulcer. | |
Corsetti et al. | Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation | |
Robertson et al. | Cisapride in the treatment of gastro‐oesophageal reflux disease | |
GB2244918A (en) | Pharmaceutical compositions comprising somatosatin and cholanic acid derivatives | |
Scarpignato | The place of octreotide in the medical management of the dumping syndrome | |
M’Koma et al. | Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones | |
Ahlman et al. | Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome. | |
Holt et al. | Peptic ulcer disease: Physiology and pathophysiology | |
JP2013040206A (ja) | 消化器系の運動をイパモレリンを用いて刺激する方法 | |
KR102289089B1 (ko) | 인후두 역류질환 치료 또는 예방용 조성물 | |
RU2147884C1 (ru) | Способ лечения язвенной болезни желудка и двенадцатиперстной кишки | |
Sugiyama et al. | Determining the optimal dose of lansoprazole injection by 24-hour intragastric pH monitoring | |
EP4146221A1 (en) | Treatment of hyperuricemia | |
JP2001501224A (ja) | 胸焼けを予防及び治療するための方法及び組成物 | |
Shiratori et al. | Inhibitory Effect of Intraduodenal Administration of Somatostatin Analogue SDZ CO 61 1 on Rat Pancreatic Exocrine Secretion | |
RU2106877C1 (ru) | Способ лечения идиопатического дерматомиозита | |
JPH06107564A (ja) | ガストリン拮抗剤の新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100902 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120731 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121031 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121129 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130108 |